A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma

Theo S. Plantinga(Genmab (Netherlands)), Romana T. Netea‐Maier(Radboud University Nijmegen)
Carcinogenesis
March 13, 2013
Cited by 37


Related Papers